心脏保护性降血糖剂和痴呆风险:系统性审查和元分析
Allie Seminer1, Alfredi Mulihano1, Clare O'Brien2
1HRB Clinical Research Facility, University of Galway, Galway, Ireland.
JAMA neurology
|April 7, 2025
概括
心脏保护性降血糖疗法整体上没有降低痴呆症风险. 然而,葡萄糖类-1受体激活剂 (GLP-1RAs) 在本次元分析中显著降低了痴呆症发病率.
科学领域:
- 内分泌学和神经病学 在内分泌学和神经病学.
- 药理学和治疗学 药理学和治疗学
背景情况:
- 糖尿病是痴呆症的已知危险因素,但降血糖治疗预防认知衰退的有效性仍然不清楚.
- 研究特定心脏保护性降血糖疗法在痴呆症预防中的作用对于患者护理至关重要.
研究的目的:
- 评估心脏保护性降血糖疗法 (SGLT2is,GLP-1RAs,甲型胺,皮奥格利塔) 是否可以降低痴呆或认知障碍的风险.
- 分析与原发性痴呆症亚型和认知分数变化的关联.
主要方法:
- 在PubMed和Embase数据库中进行了系统的搜索,截至2024年7月11日.
- 包括随机临床试验,比较心脏保护性降血糖疗法与对照药物,重点关注痴呆发病率或认知变化.
- 随机效应的元分析被用于组合治疗效应,遵守PRISMA指南.
主要成果:
- 分析了26项试验,共有164,531名参与者. 总的来说,心脏保护性降血糖疗法与降低痴呆风险没有显著的关联 (OR,0.83 [95% CI,0.60-1.14]).
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 显示,在统计学上显著降低了痴呆风险 (OR,0.55 [95% CI,0.35-0.86]).
- -葡萄糖携带载体-2 抑制剂 (SGLT2is) 与降低痴呆风险没有显著的关联 (OR,1.20 [95% CI,0.67-2.17]).
结论:
- 虽然不是普遍有效的,但特定的降血糖剂在痴呆症预防方面表现有前途.
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 是减少糖尿病患者痴呆发病率的潜在治疗策略.
相关概念视频
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
126
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
126
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
142
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
142
01:22Alzheimer's Disease: Treatment
133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133
01:23Dipeptidyl Peptidase 4 Inhibitors
139
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
139
01:30Dementia
74
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
74
01:06Oral Hypoglycemic Agents: Glinides
112
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
112